These include several different but complementary methods of NRL pathway inhibition including inducible gene knockout, CRISPR/Cas9 gene editing, as well as small molecule inhibition, strengthening the scientific validity of NRL as a therapeutic target for RP. This evidence concerns the gene NRL and retinitis pigmentosa 1.